Cyclopharm Ltd has released a press release.
Cyclopharm 2023 Half Year Accounts Update - Record Revenues
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cyclopharm
- Notification of buy-back - CYC
- Cyclopharm Confirms USFDA Scheduled Inspection Date
- USFDA Confirms Technegas Six Month Review Period
- Technegas Enters Final Six Month USFDA Review Cycle
- Dividend/Distribution - CYC
Later from Cyclopharm
- USFDA Approval Process Update
- Half Year Accounts
- Litigation Update and Receipt of Settlement Payment
- Cyclopharm Investor Update
- Investor Presentation Correction
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm